New drug combo shows promise in shrinking advanced kidney tumors before surgery
NCT ID NCT04393350
First seen Apr 26, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the drugs for 12 weeks, then have surgery to remove the tumor. The goal is to see how many patients have a significant reduction in tumor size. This approach aims to make surgery more effective and potentially improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.